Mimicking H3 Substrate Arginine in the Design of G9a Lysine Methyltransferase Inhibitors for Cancer Therapy: A Computational Study for Structure-Based Drug Design

by M. Ramya Chandar Charles, Mu-Chun Li, Hsing-Pang Hsieh, Mohane Selvaraj Coumar
Published 2021-02-01

Colloidal Assemblies Composed of Polymeric Micellar/Emulsified Systems Integrate Cancer Therapy Combining a Tumor-Associated Antigen Vaccine and Chemotherapeutic Regimens

by Chiung-Yi Huang, Shu-Yu Lin, Tsu-An Hsu, Hsing-Pang Hsieh, Ming-Hsi Huang
Published 2021-07-01

Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts.

by Li Liu, Haley Beck, Xiaolei Wang, Hsing-Pang Hsieh, Ralph P Mason, Xinli Liu
Published 2012-01-01

An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.

by Xiaolei Wang, Erxi Wu, Jun Wu, Tian-Li Wang, Hsing-Pang Hsieh, Xinli Liu
Published 2013-01-01

Design of drug-like hepsin inhibitors against prostate cancer and kidney stones

by Vincent Blay, Mu-Chun Li, Sunita P. Ho, Mashall L. Stoller, Hsing-Pang Hsieh, Douglas R. Houston
Published 2020-07-01

Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer

by Safiulla Basha Syed, Hemant Arya, I-Hsuan Fu, Teng-Kuang Yeh, Latha Periyasamy, Hsing-Pang Hsieh, Mohane Selvaraj Coumar
Published 2017-08-01

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.

by Chun Hei Antonio Cheung, Su-Ying Wu, Tian-Ren Lee, Chi-Yen Chang, Jian-Sung Wu, Hsing-Pang Hsieh, Jang-Yang Chang
Published 2010-01-01

Briarenols W–Z: Chlorine-Containing Polyoxygenated Briaranes from Octocoral <i>Briareum stechei</i> (Kükenthal, 1908)

by You-Ying Chen, Yi-Lin Zhang, Gene-Hsiang Lee, Lun Kelvin Tsou, Mingzi M. Zhang, Hsing-Pang Hsieh, Jih-Jung Chen, Chou-Yuan Ko, Zhi-Hong Wen, Ping-Jyun Sung
Published 2021-01-01

Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors.

by Kai-Cheng Hsu, Hui-Chen Hung, Jim-Tong Horng, Ming-Yu Fang, Chun-Yu Chang, Ling-Ting Li, I-Jung Chen, Yun-Chu Chen, Ding-Li Chou, Chun-Wei Chang, Hsing-Pang Hsieh, Jinn-Moon Yang, John T-A Hsu
Published 2013-01-01

BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.

by Chun Hei Antonio Cheung, Wen-Hsing Lin, John Tsu-An Hsu, Tzyh-Chyuan Hour, Teng-Kuang Yeh, Shengkai Ko, Tzu-Wen Lien, Mohane Selvaraj Coumar, Jin-Fen Liu, Wen-Yang Lai, Hui-Yi Shiao, Tian-Ren Lee, Hsing-Pang Hsieh, Jang-Yang Chang
Published 2011-01-01